Genome Biologics Enters Into a Research Collaboration and Exclusive License Option Agreement with Leading Biopharmaceutical Company
Genome Biologics enters into a research collaboration and exclusive license option agreement with leading biopharmaceutical company to identify drivers of cardiac regeneration and recovery in Myocardial Infarction (MI), Heart Failure (HF) and Cardiotoxici
Frankfurt, Germany -- Genome Biologics UG, Frankfurt, Germany, today announced that they have entered into a research collaboration with AstraZeneca related to screening of proteins of the human secretome able to drive cardiac regeneration and recovery in Myocardial Infarction (MI), Heart Failure (HF) and Cardiotoxicity (CT).
Cardiovascular disease (CVD) remains the leading cause of death and disability globally, with WHO estimating 17.9 million lives are lost to CVD each year, with one third of these deaths occurring in people under 70 years of age and incurring more than $30B / year in healthcare related costs for individuals and governments. In Germany, Cardiovascular diseases are the leading cause of death, causing a total of approximately 40% of all deaths, and 63% of annual deaths in Europe, with chronic disease including CVD costing nearly 1% of GDP.
'We are delighted to enter into this agreement with AstraZeneca Open Innovation and believe our integrated discovery platform with our unique TrueCardium™ human heart organoids has the potential to accelerate drug development and lead to new and innovative medicines to treat three very high unmet need areas of cardiovascular disease', said Jonathan Ward, CEO of Genome Biologics.
The financial terms of the agreement have not been disclosed.